Oramed Oral Insulin End-of-Ph2 FDA Meeting Provides Ph3 Development Clarity
Oramed announced it had a positive end-of-Ph2 meeting with FDA for its oral insulin (ORMD-0801). Following the meeting, Oramed said it plans to initiate two concurrent Ph3 trials. The company did not provide an updated timeline for Ph3 trial initiation, but it previously indicated the trials would begin in Q3 ’20 (previous FENIX insight). Below, FENIX provides brief thoughts on the Oramed news, including readthrough to Biocon’s oral insulin tregopil.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.